Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission ...
Revenue increased 34.0% to $157.5 million in the Fourth quarter of 2025, compared to $117.6 million in the Fourth quarter of 2024. Sertifi contributed $14.2 million in revenue in the Fourth quarter of ...
Accelerating strategic pivot to Navitas 2.0 with focus on GaN and high-voltage SiC solutions targeting high growth, high-power markets (AI Data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results